Brokerages Set Prestige Consumer Healthcare Inc. (NYSE:PBH) Target Price at $93.33

Prestige Consumer Healthcare Inc. (NYSE:PBH - Get Free Report) has been given a consensus rating of "Moderate Buy" by the six ratings firms that are covering the firm, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1-year price target among analysts that have covered the stock in the last year is $93.33.

Several equities analysts have weighed in on PBH shares. Oppenheimer raised their target price on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the company an "outperform" rating in a report on Thursday, February 13th. Royal Bank of Canada upgraded Prestige Consumer Healthcare to a "hold" rating in a report on Thursday, May 8th. DA Davidson raised their target price on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the company a "buy" rating in a report on Friday, February 7th. Wall Street Zen upgraded Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a report on Saturday, May 17th. Finally, Canaccord Genuity Group raised their target price on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the company a "buy" rating in a report on Friday, February 7th.

Insider Activity

In other news, SVP Mary Beth Fritz sold 1,678 shares of the firm's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $90.00, for a total value of $151,020.00. Following the sale, the senior vice president now directly owns 17,157 shares of the company's stock, valued at approximately $1,544,130. This trade represents a 8.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Prestige Consumer Healthcare

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Cerity Partners LLC grew its position in Prestige Consumer Healthcare by 3.7% during the first quarter. Cerity Partners LLC now owns 3,666 shares of the company's stock worth $315,000 after buying an additional 132 shares in the last quarter. Franklin Resources Inc. grew its position in Prestige Consumer Healthcare by 0.7% during the fourth quarter. Franklin Resources Inc. now owns 21,735 shares of the company's stock worth $1,697,000 after buying an additional 150 shares in the last quarter. KBC Group NV grew its position in Prestige Consumer Healthcare by 7.4% during the first quarter. KBC Group NV now owns 2,199 shares of the company's stock worth $189,000 after buying an additional 151 shares in the last quarter. CIBC Private Wealth Group LLC grew its position in Prestige Consumer Healthcare by 48.9% during the fourth quarter. CIBC Private Wealth Group LLC now owns 463 shares of the company's stock worth $34,000 after buying an additional 152 shares in the last quarter. Finally, McIlrath & Eck LLC grew its position in Prestige Consumer Healthcare by 19.1% during the fourth quarter. McIlrath & Eck LLC now owns 959 shares of the company's stock worth $75,000 after buying an additional 154 shares in the last quarter. 99.95% of the stock is owned by institutional investors and hedge funds.

Prestige Consumer Healthcare Stock Down 0.2%

NYSE PBH traded down $0.19 during trading on Monday, hitting $84.61. 283,545 shares of the company traded hands, compared to its average volume of 299,531. Prestige Consumer Healthcare has a 12 month low of $63.79 and a 12 month high of $90.04. The business has a fifty day simple moving average of $83.58 and a 200 day simple moving average of $82.48. The company has a current ratio of 3.68, a quick ratio of 2.20 and a debt-to-equity ratio of 0.56. The company has a market capitalization of $4.18 billion, a P/E ratio of 19.81, a PEG ratio of 2.69 and a beta of 0.44.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported $1.32 earnings per share for the quarter, beating the consensus estimate of $1.30 by $0.02. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. The company had revenue of $296.52 million for the quarter, compared to analyst estimates of $289.36 million. During the same period last year, the company earned $1.02 earnings per share. The business's revenue was up 7.0% compared to the same quarter last year. As a group, sell-side analysts predict that Prestige Consumer Healthcare will post 4.5 EPS for the current year.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.